Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial

Reno Eufemon Cereno, Benjamin Mou, Sarah Baker, Nick Chng, Gregory Arbour, Alanah Bergman, Mitchell Liu, Devin Schellenberg, Quinn Matthews, Vicky Huang, Ante Mestrovic, Derek Hyde, Abraham Alexander, Hannah Carolan, Fred Hsu, Stacy Miller, Siavash Atrchian, Elisa Chan, Clement Ho, Islam Mohamed, Angela Lin, Tanya Berrang, Andrew Bang, Will Jiang, C. Lund, Howard Pai, Boris Valev, Shilo Lefresne, Scott Tyldesley, Robert Olson